title: Novel approaches and perspectives in allergen immunotherapy.
abstract: In this review, we report on relevant current topics in allergen immunotherapy (AIT) which were broadly discussed during the first Aarhus Immunotherapy Symposium (Aarhus, Denmark) in December 2015 by leading clinicians, scientists and industry representatives in the field. The aim of this symposium was to highlight AIT-related aspects of public health, clinical efficacy evaluation, mechanisms, development of new biomarkers and an overview of novel therapeutic approaches. Allergy is a public health issue of high socioeconomic relevance, and development of evidence-based action plans to address allergy as a public health issue ought to be on national and regional agendas. The underlying mechanisms are in the focus of current research that lays the ground for innovative therapies. Standardization and harmonization of clinical endpoints in AIT trials as well as current knowledge about potential biomarkers have substantiated proof of effectiveness of this disease-modifying therapeutic option. Novel treatments such as peptide immunotherapy, intralymphatic immunotherapy and use of recombinant allergens herald a new age in which AIT may address treatment of allergy as a public health issue by reaching a large fraction of patients.
authors.affiliation: Department of Clinical Medicine, HEALTH, Aarhus University, Aarhus, Denmark.|Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.
authors.forename: H J
authors.identifier: http://orcid.org/0000-0002-6743-7931
authors.initials: HJ
authors.lastname: Hoffmann
authors.affiliation: Department of Lung Diseases and Clinical Immunology, University of Turku, Turku, Finland.|Filha, Finnish Lung Health Association, Helsinki, Finland.|Terveystalo Allergy Clinic Turku, Finland.
authors.forename: E
authors.initials: E
authors.lastname: Valovirta
authors.affiliation: Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Heidelberg University, Mannheim, Germany.|Center for Rhinology and Allergology, Wiesbaden, Germany.
authors.forename: O
authors.identifier: http://orcid.org/0000-0003-4374-9639
authors.initials: O
authors.lastname: Pfaar
authors.affiliation: Research and Development, StallergenesGreer, Antony Cedex, France.
authors.forename: P
authors.initials: P
authors.lastname: Moingeon
authors.affiliation: Department of Clinical Medicine, HEALTH, Aarhus University, Aarhus, Denmark.|Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.
authors.forename: J M
authors.initials: JM
authors.lastname: Schmid
authors.affiliation: Department of Clinical Medicine, HEALTH, Aarhus University, Aarhus, Denmark.|Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.
authors.forename: S H
authors.initials: SH
authors.lastname: Skaarup
authors.affiliation: Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.|Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: L-O
authors.initials: LO
authors.lastname: Cardell
authors.affiliation: Anergis SA, BioPole III, Epalinges, Switzerland.
authors.forename: K
authors.initials: K
authors.lastname: Simonsen
authors.affiliation: Clinical Immunology & Allergy and Respirology Divisions, Department of Medicine, McMaster University, Hamilton, ON, Canada.|Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Larché
authors.affiliation: Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, UK.
authors.forename: S R
authors.initials: SR
authors.lastname: Durham
authors.affiliation: Research and Development, StallergenesGreer, Antony Cedex, France.|Department of Biomedicine, HEALTH, Aarhus University & Research, Aarhus, Denmark.
authors.forename: P
authors.initials: P
authors.lastname: Sørensen
mesh_terms: D000485:Allergens / Q000276:immunology*; D015415:Biomarkers; D002986:Clinical Trials as Topic; D003888:Desensitization, Immunologic / Q000009:adverse effects / Q000379:methods; D019468:Disease Management; D006801:Humans; D006967:Hypersensitivity / Q000175:diagnosis / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy*; D007108:Immune Tolerance; D016896:Treatment Outcome
chemical_list: D000485:Allergens; D015415:Biomarkers
keywords: biomarker; clinical endpoints; intralymphatic immunotherapy; peptide immunotherapy; public health